Congress·In Committee·H.R. 5461

Type 1 Diabetes: Extending Research and Treatment Funding

Special Diabetes Program Reauthorization Act of 2025

6 months ago·View on Congress.gov·Read full text

⏸

Stalled

No legislative action in over 90 days.

Legislative Progress

House

Senate

President

Law

Key Points

This bill, introduced by Representative DeGette, would provide $160 million each year from 2026 through 2030 to support Type 1 diabetes research. This adds up to a total of $800 million over five years to help scientists find better treatments and a potential cure.
The funding supports the Special Diabetes Program, which focuses on a disease that affects millions of Americans. Unlike Type 2 diabetes, Type 1 is an autoimmune condition that cannot be prevented by diet or exercise, making medical research essential for those living with it.
By extending this program, the government ensures that long-term medical studies and clinical trials can continue without stopping. This steady funding helps develop new tools, like better insulin pumps and continuous glucose monitors, that make daily life easier for patients.
This is a renewal of an existing program that has been around for decades. If Congress does not pass this or a similar bill, the current funding would eventually stop, which could delay the discovery of new medicines and technologies.

Milestones

2 milestones2 actions

Sep 18, 2025House

Referred to the House Committee on Energy and Commerce.

Sep 18, 2025

Introduced in House

Related News

2 articles

MedPage Today·2 months ago

Health Groups Pleased With Proposed NIH Budget in Bipartisan Funding Bill

Medical organizations praised a joint House-Senate bill that extends funding for the Special Diabetes Program. The extension allows the NIDDK to continue cutting-edge Type 1 research and supports the Indian Health Service in treating communities with high diabetes prevalence.

The Portland Press Herald·7 months ago

Brunswick 7-year-old advocates for diabetes research funding in D.C.

Youth delegates met with members of Congress to urge the renewal of the Special Diabetes Program, which provides $160 million annually to the NIH. The advocacy comes as the program faces a September expiration, highlighting the need for sustained federal investment in T1D treatments.

C+